Voter skepticism toward Proposition 38, the $8.4 billion general obligation bond for immunology and immunotherapy research on the November 2026 ballot, underpins the narrow trader consensus favoring rejection. The measure would allocate half the proceeds to a UC-affiliated institute meeting narrow eligibility criteria that appear tailored to one existing nonprofit, while directing the balance to competitive grants focused on cancer, heart disease, and Alzheimer’s. Critics, including former NIH officials, have highlighted risks of fragmented state science policy, long-term General Fund repayment obligations averaging roughly $500 million annually, and the prominent role of a billionaire backer with ties to the designated recipient. Early coverage of these structural details and fiscal trade-offs has shaped the current implied probability ahead of broader polling or campaign spending.
Polymarket ডেটা রেফারেন্স করে পরীক্ষামূলক AI-জেনারেটেড সারাংশ। এটি ট্রেডিং পরামর্শ নয় এবং এই মার্কেট কীভাবে রেজলভ হয় তাতে কোনো ভূমিকা রাখে না। · আপডেটেডCalifornia Immunology Research Bond Proposition
California Immunology Research Bond Proposition
0% সম্ভাবনা
নতুন
নতুন
Nov 3, 2026
0% সম্ভাবনা
নতুন
নতুন
Nov 3, 2026
Proposition 38 is a California ballot measure currently scheduled for voting on November 3, 2026. It would allow the state to borrow $8.4 billion in debt to research immune system-based technologies for treating conditions including cancer, heart disease and Alzheimer’s.
This market will resolve to “Yes” if the specified ballot measure is approved by a majority of voters at the California statewide general election currently scheduled for November 3, 2026. Otherwise, this market will resolve to “No.”
If voting on the specified ballot measure does not occur, or the results thereof are not known definitively, by March 31, 2027, this market will resolve to “No”.
This market will resolve based on a consensus of credible reporting. If there is ambiguity, this market will resolve solely based on official information from the State of California, including the California Secretary of State (https://www.sos.ca.gov/).Voter skepticism toward Proposition 38, the $8.4 billion general obligation bond for immunology and immunotherapy research on the November 2026 ballot, underpins the narrow trader consensus favoring rejection. The measure would allocate half the proceeds to a UC-affiliated institute meeting narrow eligibility criteria that appear tailored to one existing nonprofit, while directing the balance to competitive grants focused on cancer, heart disease, and Alzheimer’s. Critics, including former NIH officials, have highlighted risks of fragmented state science policy, long-term General Fund repayment obligations averaging roughly $500 million annually, and the prominent role of a billionaire backer with ties to the designated recipient. Early coverage of these structural details and fiscal trade-offs has shaped the current implied probability ahead of broader polling or campaign spending.
Proposition 38 is a California ballot measure currently scheduled for voting on November 3, 2026. It would allow the state to borrow $8.4 billion in debt to research immune system-based technologies for treating conditions including cancer, heart disease and Alzheimer’s.
This market will resolve to “Yes” if the specified ballot measure is approved by a majority of voters at the California statewide general election currently scheduled for November 3, 2026. Otherwise, this market will resolve to “No.”
If voting on the specified ballot measure does not occur, or the results thereof are not known definitively, by March 31, 2027, this market will resolve to “No”.
This market will resolve based on a consensus of credible reporting. If there is ambiguity, this market will resolve solely based on official information from the State of California, including the California Secretary of State (https://www.sos.ca.gov/).
This market will resolve to “Yes” if the specified ballot measure is approved by a majority of voters at the California statewide general election currently scheduled for November 3, 2026. Otherwise, this market will resolve to “No.”
If voting on the specified ballot measure does not occur, or the results thereof are not known definitively, by March 31, 2027, this market will resolve to “No”.
This market will resolve based on a consensus of credible reporting. If there is ambiguity, this market will resolve solely based on official information from the State of California, including the California Secretary of State (https://www.sos.ca.gov/).
মার্কেট ওপেন হয়েছে: Jul 1, 2026, 6:33 PM ET
ভলিউম
$2,851শেষ তারিখ
Nov 3, 2026মার্কেট ওপেন হয়েছে
Jul 1, 2026, 6:33 PM ETResolver
0x65070BE91...Proposition 38 is a California ballot measure currently scheduled for voting on November 3, 2026. It would allow the state to borrow $8.4 billion in debt to research immune system-based technologies for treating conditions including cancer, heart disease and Alzheimer’s.
This market will resolve to “Yes” if the specified ballot measure is approved by a majority of voters at the California statewide general election currently scheduled for November 3, 2026. Otherwise, this market will resolve to “No.”
If voting on the specified ballot measure does not occur, or the results thereof are not known definitively, by March 31, 2027, this market will resolve to “No”.
This market will resolve based on a consensus of credible reporting. If there is ambiguity, this market will resolve solely based on official information from the State of California, including the California Secretary of State (https://www.sos.ca.gov/).Voter skepticism toward Proposition 38, the $8.4 billion general obligation bond for immunology and immunotherapy research on the November 2026 ballot, underpins the narrow trader consensus favoring rejection. The measure would allocate half the proceeds to a UC-affiliated institute meeting narrow eligibility criteria that appear tailored to one existing nonprofit, while directing the balance to competitive grants focused on cancer, heart disease, and Alzheimer’s. Critics, including former NIH officials, have highlighted risks of fragmented state science policy, long-term General Fund repayment obligations averaging roughly $500 million annually, and the prominent role of a billionaire backer with ties to the designated recipient. Early coverage of these structural details and fiscal trade-offs has shaped the current implied probability ahead of broader polling or campaign spending.
Proposition 38 is a California ballot measure currently scheduled for voting on November 3, 2026. It would allow the state to borrow $8.4 billion in debt to research immune system-based technologies for treating conditions including cancer, heart disease and Alzheimer’s.
This market will resolve to “Yes” if the specified ballot measure is approved by a majority of voters at the California statewide general election currently scheduled for November 3, 2026. Otherwise, this market will resolve to “No.”
If voting on the specified ballot measure does not occur, or the results thereof are not known definitively, by March 31, 2027, this market will resolve to “No”.
This market will resolve based on a consensus of credible reporting. If there is ambiguity, this market will resolve solely based on official information from the State of California, including the California Secretary of State (https://www.sos.ca.gov/).
This market will resolve to “Yes” if the specified ballot measure is approved by a majority of voters at the California statewide general election currently scheduled for November 3, 2026. Otherwise, this market will resolve to “No.”
If voting on the specified ballot measure does not occur, or the results thereof are not known definitively, by March 31, 2027, this market will resolve to “No”.
This market will resolve based on a consensus of credible reporting. If there is ambiguity, this market will resolve solely based on official information from the State of California, including the California Secretary of State (https://www.sos.ca.gov/).
ভলিউম
$2,851শেষ তারিখ
Nov 3, 2026মার্কেট ওপেন হয়েছে
Jul 1, 2026, 6:33 PM ETResolver
0x65070BE91...Voter skepticism toward Proposition 38, the $8.4 billion general obligation bond for immunology and immunotherapy research on the November 2026 ballot, underpins the narrow trader consensus favoring rejection. The measure would allocate half the proceeds to a UC-affiliated institute meeting narrow eligibility criteria that appear tailored to one existing nonprofit, while directing the balance to competitive grants focused on cancer, heart disease, and Alzheimer’s. Critics, including former NIH officials, have highlighted risks of fragmented state science policy, long-term General Fund repayment obligations averaging roughly $500 million annually, and the prominent role of a billionaire backer with ties to the designated recipient. Early coverage of these structural details and fiscal trade-offs has shaped the current implied probability ahead of broader polling or campaign spending.
Polymarket ডেটা রেফারেন্স করে পরীক্ষামূলক AI-জেনারেটেড সারাংশ। এটি ট্রেডিং পরামর্শ নয় এবং এই মার্কেট কীভাবে রেজলভ হয় তাতে কোনো ভূমিকা রাখে না। · আপডেটেড
বাহ্যিক লিংক থেকে সাবধান।
বাহ্যিক লিংক থেকে সাবধান।
সচরাচর জিজ্ঞাসা